Skip to Main content Skip to Navigation
Journal articles

Drug resistance in glioblastoma: are persisters the key to therapy?

Lisa Oliver 1 Lisenn Lalier 1 Céline Salaud 1 Dominique Heymann 1 Pierre Francois Cartron 1 François Vallette 1
1 CRCINA-ÉQUIPE 9 - Apoptosis and Tumor Progression
CRCINA - Centre de Recherche en Cancérologie et Immunologie Nantes-Angers
Abstract : Glioblastoma (GBM) represents the main form of brain tumors in adults, and one of the most aggressive cancers overall. The treatment of GBM is a combination of surgery (when possible), chemotherapy (usually Temozolomide, TMZ) and radiotherapy (RT). However, despite this heavy treatment, GBM invariably recur and the median length of survival following diagnosis is 12 to 15 months, with less than 10% of people surviving longer than five years. GBM is extremely resistant to most treatments because of its heterogeneous nature, which is associated with extreme clonal plasticity and the presence of cancer stem cells, refractory to TMZ- and RT-induced cell death. In this review, we explore the mechanisms by which cancer cells, and especially GBM, can acquire resistance to treatment. We describe and discuss the concept of persister/tolerant cells that precede and/or accompany the acquisition of resistance. Persister/tolerant cells are cancer cells that are not eliminated by treatment(s) because of different mechanisms ranging from dormancy/quiescence to senescence. We discuss the possibility of targeting these mechanisms in new therapeutic regimen.
Document type :
Journal articles
Complete list of metadatas

Cited literature [96 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-02913818
Contributor : Elizabeth Bernardo <>
Submitted on : Monday, August 10, 2020 - 4:02:38 PM
Last modification on : Tuesday, August 11, 2020 - 3:29:31 AM

File

CancerDrugResis2020.pdf
Publication funded by an institution

Identifiers

Collections

Citation

Lisa Oliver, Lisenn Lalier, Céline Salaud, Dominique Heymann, Pierre Francois Cartron, et al.. Drug resistance in glioblastoma: are persisters the key to therapy?. Cancer Drug Resistance, oaepublish, 2020, 3, Online ahead of print. ⟨10.20517/cdr.2020.29⟩. ⟨inserm-02913818⟩

Share

Metrics

Record views

85

Files downloads

87